BioCentury
ARTICLE | Clinical News

Antisense oligonucleotide: Interim Phase II data

September 7, 2009 7:00 AM UTC

In a double-blind, vehicle-controlled Phase II trial in 40 patients who did not respond to conventional therapy, 86 µg/day GS-101 met the primary endpoint of inhibition and regression of corneal neova...